#279 P.007/013

RECEIVED CENTRAL FAX CENTER

FEB 0 9 2009

49.-52. (Canceled)

53. (Currently Amended) The method of claim 1, wherein selecting the

different droplet size includes selecting a medicament composition including the

bioactive agent with the same drug for each different droplet size.

54. (Currently Amended) The method of claim 1, wherein ejecting

medicament droplets includes ejecting medicament droplets having the bioactive

agent a-drug and a flavoring agent and sized for deposition on an oral mucosal region

and further includes ejecting medicament droplets having the bioactive agent [[drug]]

and sized for deposition on a pulmonary mucosal region.

55. (Currently Amended) The method of claim 1, wherein ejecting

medicament droplets includes ejecting medicament droplets having the bioactive

agent a drug and sized for deposition on an oral mucosal region, further comprising

ejecting placebo droplets without the bioactive agent [[drug]] and sized for deposition

on an oral mucosal region.

(Currently Amended) The method of claim 55, wherein the treatment plan 56.

restricts when the bioactive agent [[drug]] can be ejected, and wherein ejecting

placebo droplets without the bioactive agent [[drug]] to an oral mucosal region is

performed instead of ejecting medicament droplets having the bioactive agent [[drug]]

to an oral mucosal region if ejecting the bioactive agent [[drug]] is restricted currently

by the elapsed time treatment plan.

57. (Currently Amended) The method of claim 55, wherein ejecting

medicament droplets having the bioactive agent a drug to an oral mucosal region

Page 6 -

RESPONSE TO FINAL OFFICE ACTION

Serial No.: 10/756,449

HP Docket No.: 200208788-1 KH Docket No.: HPCC 386

From: 02/09/2009 16:09 #279 P.008/013

includes ejecting medicament droplets having a flavoring agent, and wherein ejecting

placebo droplets to an oral mucosal region includes ejecting placebo droplets having

the flavoring agent.

58. (New) The method of claim 1, wherein ejecting medicament droplets

includes ejecting relatively larger and relatively smaller droplets each including the

bioactive agent, and wherein the larger droplets are selected for ejection in the later

dose only if the elapsed time is above a threshold.

Page 7 - RESPONSE TO FINAL OFFICE ACTION

Serial No.: 10/756,449

HP Docket No.: 200208788-1 KH Docket No.: HPCC 386